Cigna Group Stock (NYSE:CI), Trade Ideas

Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 18 million US medical members covered as of December 2023.

Cigna

pharmaceutical

Large Cap

News

Health Care

General

ABBV

Evernorth Health Services&#39; initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average of $3,500 yearly.

Arthritis Patients - Cigna&#39;s Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost

Insurance stock image

Biotech

Debate ensues over insurance coverage for Novo Nordisk&#39;s Wegovy following FDA approval. Evernorth&#39;s EncircleRx introduces financial guarantee, aiming to control costs and improve accessibility. Insurers face pressure to include weight loss drugs amid rising healthcare expenses.

Inconsistent Insurance Coverage For Weight Loss Drugs - Novo Nordisk&#39;s GLP-1s Face Hurdles Despite Health Benefits

Price Target

Markets

Analyst Ratings

Trading Ideas

AVGO

COST

MRVL

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Broadcom To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday

The Cigna Group

Citizens, Inc. Class A Common Stock ($1.00 Par)

Citizens Inc

CHINA MENGNIU DAIRY CO by China Mengniu Dairy Co., Ltd.

China Mengniu Dairy Co Ltd

CHINA MENGNIU DARY UN/ADR by China Mengniu Dairy Co., Ltd.

CHAMPION IRON LTD by Champion Iron Limited

Champion Iron Ltd

China Score Inc

BanColombia SA

COMML INTL BK S/ADR by Commercial International Bank Ltd.

Commercial International Bank - Egypt CIB

CIB MARINE BANCSHARES by CIB Marine Bancshares, Inc.

CIB Marine Bancshares Inc

COMMUTY INV BANCORP INC by Community Investors Bancorp, Inc.

Community Investors Bancorp Inc

First Trust NASDAQ Cybersecurity ETF

CIBL Inc

Capitol Investment Corp. VII

CHINA CONSTR BANK H by China Construction Bank Corp.

China Construction Bank Corp

CHINA CONSTR BK UNSP/ADR by China Construction Bank Corp.

SMS ALTERNATIVES INC by SMS Alternatives Inc.

SMS Alternatives Inc

COSCO SHIPPING HLDGS CO by COSCO SHIPPING Holdings Co Ltd.

COSCO SHIPPING Holdings Co Ltd

COSCO SHP HLDG UNSP/ADR by COSCO SHIPPING Holdings Co Ltd.

Capitol Investment Corp. VI

VictoryShares International High Div Volatility Wtd ETF

Ciena Corp

CHieru Co Ltd

CORPORACION INTERAMER B by Corporacion Intramericano Entretenimiento S.A.

Corporacion Interamericana de Entretenimiento SAB de CV

MFS Intermediate High Income Fund Common Stock

Mfs Intermediate High Income Fund

Cipher Mining Inc

Comp En De Mn Cemig ADS American Depositary Shares

Cia Energetica DE Minas Gerais - Cemig

Comp En De Mn Cemig ADS American Depositary Receipts

Colliers International Group Inc. - Subordinate Voting Shares

Colliers International Group Inc

CI Games SE

CHINA MERCHANTS BK CO H by China Merchants Bank Co., Ltd.

China Merchants Bank Co Ltd

CHINA MRCHNTS BK UNSP/ADR by China Merchants Bank Co., Ltd.

CB INDUS PRODUCT HLDG BHD by CB Industrial Product Holding BHD

CB Industrial Product Holding Bhd

Blackrock Enhanced Cap&Inc Fund, Inc

CITIC SECURITIES CO LTD H by Citic Securities Co., Ltd.

CITIC Securities Co Ltd

CITIC SECURITIES UNSP/ADR by Citic Securities Co., Ltd.

TIANCI INTERNATIONAL INC by Tianci International Inc.

Tianci International Inc

Credit Suisse Asset Management Income Fund, Inc. Common Stock

Credit Suisse Asset Mgmt Income Fund Inc

VictoryShares International Volatility Wtd ETF

CHINA LIFE INS CO H SHS by China Life Insurance Company Limited

China Life Insurance Co Ltd

CAROLINA MILLS INC by Carolina Mills, Inc.

Carolina Mills Inc

Chimera Investment Corporation Common Stock

Chimera Investment Corp

CIMB GROUP HLDGS BHD ORD by CIMB Group Holdings BHD

CIMB Group Holdings Bhd

CIMC ENRIC HLDGS LTD ORD by CIMC Enric Holdings Ltd.

CIMC Enric Holdings Ltd

Pideka Group Inc

CIMAREX ENERGY 8 1/8 PFD by Cimarex Energy Co.

Cimarex Energy Co

Chimera Investment Corporation 8.00% Series A Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series B Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 7.75% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

CHINA INDUSTRIAL GRP INC by China Industrial Group, Inc.

China Industrial Group

Cincinnati Financial Corporation - Common Stock

Cincinnati Financial Corp

Cingulate Inc

COINSILIUM GROUP LTD ORD by Coinsilium Group Ltd.

Coinsilium Group Ltd

CHINA TAIPING INS HLD ORD by China Taiping Insurance Holdings Co Ltd.

China Taiping Insurance Holdings Co Ltd

CI&T Inc

CRUCIAL INNOVATIONS CORP by CRUCIAL INNOVATIONS CORP.

Crucial Innovations Corp

City Office REIT Inc

CION Invt Corp

Cielo SA

City Office REIT, Inc. 6.625% Series A Cumulative Redeemable Preferred Stock

CORRELATE ENERGY CORP by Correlate Energy Corp.

Correlate Energy Corp

JPMorgan Exchange-Traded Fund Trust Sustainable Consumption ETF

Cirus Foundation

CirTran Corp

Ciscom Corp

CHINA STEEL CP S/ADR 144A by China Steel Corp.

China Steel Corp

CISO Global Inc

C3is Inc

CHINA STEEL CORP S/GDR by China Steel Corp.

COSCO SHIPPING DEV CO LTD by Cosco Shipping Development Co Ltd.

Cosco Shipping Development Co Ltd

COSCO SHIP DEV UNSP/ADR by Cosco Shipping Development Co Ltd.

Cartica Acquisition Corp - Class A Ordinary Shares

Cartica Acquisition Corp

CRITICAL INFRASTUCTRE TCH by Critical Infrastructure Technologies Ltd.

Critical Infrastructure Technologies Ltd

AVALON CORRECTIONAL INC by Avalon Correctional Services, Inc.

Manchester City Fan Token

CITIZENS BANCSHARES CP SC by Citizens Bancshares Corp South Carolina

Citizens Bancshares Corp

Civilization

Civista Bancshares Inc

Civitas Resources Inc

Civitas Resources Inc Warrants (20/01/2026)

Civitas Resources Inc Warrants (20/01/2025)

CTR INVTS&CNSLTNG INC by CTR Investments & Consulting, Inc.

CTR Investments & Consulting Inc

CHINA INDL WASTE MGMT INC by China Industrial Waste Management, Inc.

China Industrial Waste Management Inc

CITZNS FINCL CORP W VA by Citizens Financial Corp. (WV)

Citizens Financial Corp WV

Compx International Inc

CaixaBank SA

CI Financial Corp

VictoryShares Developed Enhanced Volatility Wtd ETF

CITZNS HOLDINGS CO MISS by Citizens Holding Co.

Citizens Holding Co

On Thursday, Evernorth Health Services said its Accredo arm will make a Humira biosimilar available to patients with no <a href="https://www.benzinga.com/pressreleases/24/04/n38444988/evernorth-announces-humira-biosimilar-available-at-0-out-of-pocket-for-accredo-patients-in-june" target="_blank" rel="noreferrer noopener">out-of-pocket costs</a>. Evernorth is a subsidiary of The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>).
Beginning in June, the high- and low-concentration interchangeable biosimilar will&nbsp;be produced&nbsp;for Evernorth&#8217;s affiliate private-label pharmaceutical distributor, Quallent Pharmaceuticals, through agreements&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/07/33386891/seven-humira-biosimilars-increased-competition-in-arthritis-drug-market-sparks-need-for-reform-of" rel="noreferrer noopener">with multiple manufacturers</a>.
Most patients will be able to secure the biosimilar products for $0 out-of-pocket through the copay assistance programs offered at Quallent beginning in June, Evernorth said.
This program is estimated to save individual patients around&nbsp;$3,500&nbsp;on average per year.
According to the announcement, the biosimilar price is about 85% lower than that of branded Humira.&nbsp;More than 100,000 Accredo patients use either Humira or one of its biosimilars, the company said.
The specialty pharmacy provides patients with a Therapeutic Resource Center&nbsp;to&nbsp;connect to specialty-trained pharmacists and nurses who are available&nbsp;around the clock.&nbsp;Accredo&#8217;s centers cover 15 specific conditions.
Humira is&nbsp;AbbVie&nbsp;Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) blockbuster arthritis drug. In the most recent first-quarter earnings, Humira generated sales of&nbsp;$2.27 billion&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38460664/ex-humira-growth-platform-drives-abbvies-q1-performance-drugmaker-lifts-annual-profit-outlook" rel="noreferrer noopener">(down 35.9%&nbsp;Y/Y)</a>.
Reuters notes that AbbVie has held onto more than 98% of the Humira market despite nine biosimilars being launched in the U.S. last year.&nbsp;
Citing IQVIA data,&nbsp;Reuters highlighted that privately-held German drugmaker Boehringer launched its version, Cyltezo, last July but has only sold a couple of thousand prescriptions since then.
Reuters report added that almost 3 million Humira prescriptions have been written during the same period, although&nbsp;tens of thousands of scripts have started to shift to biosimilar Hyrimoz each week since&nbsp;CVS Health&#8217;s Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) pharmacy benefits unit took Humira off the list of drugs it recommends insurers reimburse.&nbsp;
Price Action: CI shares are down 0.07% at $354.25 at the last check Friday.
Image: Phoenix Locklear from Pixabay

Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost

Financial giants have made a conspicuous bullish move on Cigna Group. Our analysis of options history for Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) revealed 11 unusual trades.
Delving into the details, we found 72% of traders were bullish, while 27% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $212,800, and 6 were calls, valued at $301,199.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $270.0 to $390.0 for Cigna Group over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cigna Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cigna Group's significant trades, within a strike price range of $270.0 to $390.0, over the past month.
<h3>Cigna Group Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713286892_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$43.3</td>
<td>$41.1</td>
<td>$43.3</td>
<td>$360.00</td>
<td>$99.5K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$43.5</td>
<td>$41.1</td>
<td>$43.3</td>
<td>$360.00</td>
<td>$55.9K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">36</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.3</td>
<td>$4.7</td>
<td>$4.7</td>
<td>$270.00</td>
<td>$50.7K</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">198</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.3</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$270.00</td>
<td>$49.6K</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">380</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/03/24</td>
<td>$9.9</td>
<td>$9.8</td>
<td>$9.8</td>
<td>$350.00</td>
<td>$49.0K</td>
<td style="text-align: right;">45</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About Cigna Group</h3>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 18 million US medical members covered as of December 2023.
After a thorough review of the options trading surrounding Cigna Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Cigna Group Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 893,618, with CI's price up by 0.07%, positioned at $349.13.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 16 days.</li>
</ul>
<h3>Professional Analyst Ratings for Cigna Group</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $384.0.
<ul>
<li>An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $384. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Cigna Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Unpacking the Latest Options Trading Trends in Cigna Group

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 5 years by 6.21% on an annualized basis producing an average annual return of 18.53%. Currently, Cigna Group has a market capitalization of $101.50 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 5 years ago, it would be worth $215.71 today based on a price of $357.84 for CI at the time of writing.
<h3>Cigna Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1712860215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Cigna Group 5 Years Ago Would Be Worth Today

Throughout the last three months, 16 analysts have evaluated Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Cigna Group and provided 12-month price targets. The average target is $375.06, accompanied by a high estimate of $400.00 and a low estimate of $334.00. This current average reflects an increase of 4.37% from the previous average price target of $359.36. 
<img src="https://www.benzinga.com/files/images/story/2024/1712757651_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Cigna Group by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$384.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$384.00</td>
<td>$372.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$383.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$385.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$393.00</td>
<td>-</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$392.00</td>
<td>$382.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$372.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$348.00</td>
<td>$334.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$372.00</td>
<td>$334.00</td>
</tr>
<tr>
<td>Frank Morgan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$354.00</td>
<td>$327.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$334.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$360.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cigna Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cigna Group compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Cigna Group's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Cigna Group's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cigna Group analyst ratings.</a>
<h2>Unveiling the Story Behind Cigna Group</h2>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 18 million US medical members covered as of December 2023.
<h3>Cigna Group's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Cigna Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.72% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Cigna Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.01%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cigna Group's ROE stands out, surpassing industry averages. With an impressive ROE of 2.24%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Cigna Group's ROA stands out, surpassing industry averages. With an impressive ROA of 0.68%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Cigna Group's debt-to-equity ratio is below the industry average at 0.67, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Cigna Group Stands With Analysts

Cantor Fitzgerald analyst Sarah James reiterates Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and maintains $384 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Cigna Group, Maintains $384 Price Target

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$25.00</td>
<td>$162.0K</td>
<td>32.5K</td>
<td>3.3K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$87.00</td>
<td>$58.1K</td>
<td>4</td>
<td>529</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$160.00</td>
<td>$28.5K</td>
<td>5.6K</td>
<td>342</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$350.00</td>
<td>$144.9K</td>
<td>254</td>
<td>286</td>
</tr>
<tr>
<td>ITCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$60.00</td>
<td>$45.0K</td>
<td>7.8K</td>
<td>228</td>
</tr>
<tr>
<td>JANX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$40.00</td>
<td>$124.0K</td>
<td>13</td>
<td>200</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/05/24</td>
<td>$135.00</td>
<td>$29.8K</td>
<td>274</td>
<td>109</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$105.00</td>
<td>$28.0K</td>
<td>5.5K</td>
<td>93</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$75.00</td>
<td>$25.0K</td>
<td>1.7K</td>
<td>73</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$780.00</td>
<td>$187.3K</td>
<td>3.2K</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a put option sweep that happens to be bullish, expiring in 78 day(s) on June 21, 2024. This event was a transfer of 3300 contract(s) at a $25.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $162.0K, with a price of $49.0 per contract. There were 32560 open contracts at this strike prior to today, and today 3361 contract(s) were bought and sold. 
• Regarding MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we observe a call option trade with bullish sentiment. It expires in 36 day(s) on May 10, 2024. Parties traded 529 contract(s) at a $87.00 strike. The total cost received by the writing party (or parties) was $58.1K, with a price of $110.0 per contract. There were 4 open contracts at this strike prior to today, and today 529 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 78 day(s) on June 21, 2024. This event was a transfer of 133 contract(s) at a $160.00 strike. The total cost received by the writing party (or parties) was $28.5K, with a price of $215.0 per contract. There were 5612 open contracts at this strike prior to today, and today 342 contract(s) were bought and sold. 
• Regarding CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we observe a put option sweep with bullish sentiment. It expires in 43 day(s) on May 17, 2024. Parties traded 230 contract(s) at a $350.00 strike. This particular put needed to be split into 40 different trades to become filled. The total cost received by the writing party (or parties) was $144.9K, with a price of $630.0 per contract. There were 254 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• For ITCI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on April 19, 2024. This event was a transfer of 225 contract(s) at a $60.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $45.0K, with a price of $200.0 per contract. There were 7828 open contracts at this strike prior to today, and today 228 contract(s) were bought and sold. 
• For JANX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>), we notice a call option trade that happens to be bearish, expiring in 134 day(s) on August 16, 2024. This event was a transfer of 200 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $124.0K, with a price of $620.0 per contract. There were 13 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we notice a put option trade that happens to be neutral, expiring in 1 day(s) on April 5, 2024. This event was a transfer of 36 contract(s) at a $135.00 strike. The total cost received by the writing party (or parties) was $29.8K, with a price of $830.0 per contract. There were 274 open contracts at this strike prior to today, and today 109 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option trade that happens to be bearish, expiring in 288 day(s) on January 17, 2025. This event was a transfer of 10 contract(s) at a $105.00 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $2800.0 per contract. There were 5583 open contracts at this strike prior to today, and today 93 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option sweep that happens to be bullish, expiring in 15 day(s) on April 19, 2024. This event was a transfer of 50 contract(s) at a $75.00 strike. This particular call needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 1747 open contracts at this strike prior to today, and today 73 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be neutral, expiring in 288 day(s) on January 17, 2025. This event was a transfer of 19 contract(s) at a $780.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $187.3K, with a price of $9854.0 per contract. There were 3204 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ITCI

JANX

SRPT

VKTX

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$460.00</td>
<td>$28.1K</td>
<td>580</td>
<td style="text-align: right;">917</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$115.00</td>
<td>$215.7K</td>
<td>1.4K</td>
<td style="text-align: right;">633</td>
</tr>
<tr>
<td>TMDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$90.00</td>
<td>$352.0K</td>
<td>40</td>
<td style="text-align: right;">489</td>
</tr>
<tr>
<td>ESTA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$52.50</td>
<td>$56.0K</td>
<td>1.3K</td>
<td style="text-align: right;">401</td>
</tr>
<tr>
<td>NVCR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$12.50</td>
<td>$35.0K</td>
<td>1.3K</td>
<td style="text-align: right;">374</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$82.50</td>
<td>$32.4K</td>
<td>325</td>
<td style="text-align: right;">351</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$195.00</td>
<td>$85.0K</td>
<td>1.0K</td>
<td style="text-align: right;">251</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/26/24</td>
<td>$70.00</td>
<td>$33.3K</td>
<td>56</td>
<td style="text-align: right;">142</td>
</tr>
<tr>
<td>INSP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$190.00</td>
<td>$34.8K</td>
<td>282</td>
<td style="text-align: right;">60</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$360.00</td>
<td>$68.2K</td>
<td>316</td>
<td style="text-align: right;">51</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option trade with bullish sentiment. It expires in 16 day(s) on April 19, 2024. Parties traded 25 contract(s) at a $460.00 strike. The total cost received by the writing party (or parties) was $28.1K, with a price of $1125.0 per contract. There were 580 open contracts at this strike prior to today, and today 917 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 79 day(s) on June 21, 2024. Parties traded 500 contract(s) at a $115.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $215.7K, with a price of $431.0 per contract. There were 1484 open contracts at this strike prior to today, and today 633 contract(s) were bought and sold. 
• Regarding TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we observe a call option trade with bearish sentiment. It expires in 261 day(s) on December 20, 2024. Parties traded 275 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $352.0K, with a price of $1280.0 per contract. There were 40 open contracts at this strike prior to today, and today 489 contract(s) were bought and sold. 
• Regarding ESTA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>), we observe a call option trade with bullish sentiment. It expires in 16 day(s) on April 19, 2024. Parties traded 200 contract(s) at a $52.50 strike. The total cost received by the writing party (or parties) was $56.0K, with a price of $280.0 per contract. There were 1305 open contracts at this strike prior to today, and today 401 contract(s) were bought and sold. 
• Regarding NVCR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>), we observe a call option sweep with bullish sentiment. It expires in 16 day(s) on April 19, 2024. Parties traded 176 contract(s) at a $12.50 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $196.0 per contract. There were 1307 open contracts at this strike prior to today, and today 374 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a call option sweep that happens to be neutral, expiring in 653 day(s) on January 16, 2026. This event was a transfer of 59 contract(s) at a $82.50 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $32.4K, with a price of $550.0 per contract. There were 325 open contracts at this strike prior to today, and today 351 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be bearish, expiring in 289 day(s) on January 17, 2025. This event was a transfer of 125 contract(s) at a $195.00 strike. The total cost received by the writing party (or parties) was $85.0K, with a price of $680.0 per contract. There were 1037 open contracts at this strike prior to today, and today 251 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a put option sweep with bullish sentiment. It expires in 23 day(s) on April 26, 2024. Parties traded 142 contract(s) at a $70.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $33.3K, with a price of $235.0 per contract. There were 56 open contracts at this strike prior to today, and today 142 contract(s) were bought and sold. 
• For INSP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>), we notice a put option sweep that happens to be bullish, expiring in 44 day(s) on May 17, 2024. This event was a transfer of 30 contract(s) at a $190.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $34.8K, with a price of $1160.0 per contract. There were 282 open contracts at this strike prior to today, and today 60 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option trade that happens to be bearish, expiring in 44 day(s) on May 17, 2024. This event was a transfer of 44 contract(s) at a $360.00 strike. The total cost received by the writing party (or parties) was $68.2K, with a price of $1550.0 per contract. There were 316 open contracts at this strike prior to today, and today 51 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ESTA

GILD

INSP

MRNA

NVCR

TMDX

WIIM

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Shares of healthcare providers are trading lower after the CMS finalized payment updates for the 2025 Medicare Advantage and Medicare Part D programs.

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 20 years by 7.07% on an annualized basis producing an average annual return of 14.95%. Currently, Cigna Group has a market capitalization of $103.06 billion. 
Buying $1000 In CI: If an investor had bought $1000 of CI stock 20 years ago, it would be worth $16,189.34 today based on a price of $363.34 for CI at the time of writing.
<h3>Cigna Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711656038_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Cigna Group 20 Years Ago Would Be Worth Today

Cigna Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) short percent of float has risen 132.71% since its last report. The company recently reported that it has 7.26 million shares sold short, which is 2.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cigna Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711474208_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cigna Group has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cigna Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cigna Group's peer group average for short interest as a percentage of float is 10.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Cigna Group's Recent Short Interest

The recent expansion of Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)&nbsp;Wegovy&#8217;s&nbsp;(semaglutide) FDA approval has sparked a debate over&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37567088/novo-nordisks-game-changer-fda-approves-weight-loss-sensation-wegovy-for-heart-health-potential-i" rel="noreferrer noopener">insurance coverage for the drug</a>.&nbsp;
However, despite its potential health benefits, some employers and health plans remain hesitant to cover the drug due to its high monthly price of $1,350 and uncertainties regarding patient adherence.
This expansion allows for a cost cap or savings guarantee, fostering accessibility for deserving patients.
Citing John Crable, Senior Vice President of Corporate Synergies, CNBC&nbsp;<a target="_blank" href="https://www.cnbc.com/2024/03/16/wegovy-heart-health-insurance-coverage.html" rel="noreferrer noopener">noted</a>&nbsp;that the growing benefits associated with weight loss drugs may increase pressure on insurers to include them in standard insurance plans.&nbsp;
However, convincing insurers to do so may require more evidence of long-term efficacy and cost-effectiveness.
While approximately 50 million insured American adults have coverage for weight loss drugs, coverage for GLP-1s remains inconsistent across different insurance plans.
Despite potential long-term cost savings and improved health outcomes associated with covering weight loss drugs, some employers, like North Carolina&#8217;s state plan, are scaling back coverage due to financial concerns.&nbsp;
North Carolina Treasurer Dale Folwell highlighted the state&#8217;s financial strain caused by covering Wegovy, which amounted to nearly $87 million last year.
CNBC noted that Novo Nordisk says its&nbsp;<a target="_blank" href="https://www.novocare.com/obesity/products/wegovy/savings-offer.html" rel="noreferrer noopener">savings program</a>&nbsp;can help patients without insurance coverage save up to $500 per 28-day supply of Wegovy.&nbsp;
The company also said roughly 80% of Wegovy patients in the U.S. with commercial coverage for the drug are paying $25 per month or less.
To address concerns over rising costs, some insurers are implementing cost control measures, such as spending caps and limits on annual spending increases for weight loss drugs.&nbsp;
Earlier this month,&nbsp;Evernorth Health Services, a subsidiary of&nbsp;Cigna Group&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), introduced a financial guarantee in its EncircleRx program.
The move aims to provide clients with predictability when covering GLP-1s, ultimately empowering companies and health plans to exercise better&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/03/37542349/insurance-coverage-for-weight-loss-drugs-cigna-unveils-efforts-to-limit-health-plansemployers-spend" rel="noreferrer noopener">control over their expenditures</a>.
According to a report in October 2023, coverage for obesity medications, including Wegovy, is expected to expand among U.S. employers.&nbsp;
The survey indicates a growing willingness among employers to include GLP-1 drugs like Wegovy in their health coverage plans amid rising healthcare costs associated with the increased popularity of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35157108/obesity-medication-insurance-coverage-employers-embrace-the-inclusion-of-novo-nordisks-wegovy-in-" rel="noreferrer noopener">such weight-loss treatments</a>.
Price Action:&nbsp;NVO shares are up 0.76% at $133.37 on the last check Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Vlad Deep for Unsplash

Inconsistent Insurance Coverage For Weight Loss Drugs - Novo Nordisk's GLP-1s Face Hurdles Despite Health Benefits

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 20 years by 7.66% on an annualized basis producing an average annual return of 15.5%. Currently, Cigna Group has a market capitalization of $100.06 billion. 
Buying $100 In CI: If an investor had bought $100 of CI stock 20 years ago, it would be worth $1,796.06 today based on a price of $342.27 for CI at the time of writing.
<h3>Cigna Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1710189013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Cigna Group 20 Years Ago Would Be Worth Today

Cantor Fitzgerald analyst Sarah James maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $372 to $384.

Cantor Fitzgerald Maintains Overweight on Cigna Group, Raises Price Target to $384

UBS analyst Kevin Caliendo maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and raises the price target from $385 to $400.

UBS Maintains Buy on Cigna Group, Raises Price Target to $400

RBC Capital analyst Ben Hendrix maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Outperform and raises the price target from $354 to $383.

RBC Capital Maintains Outperform on Cigna Group, Raises Price Target to $383

Truist Securities analyst David Macdonald reiterates Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and raises the price target from $380 to $400.

Truist Securities Reiterates Buy on Cigna Group, Raises Price Target to $400

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group raised the price target for The Gap, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gps#NYSE">GPS</a>) from $22 to $24. Evercore ISI Group analyst Michael Binetti maintained an Outperform rating. Gap shares gained 1.4% to close at $19.33 on Thursday. <a href="https://www.benzinga.com/quote/GPS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised the price target for Brunswick Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bc#NYSE">BC</a>) from $95 to $115. Jefferies analyst Anna Glaessgen maintained a Buy rating. Brunswick shares gained 2% to close at $89.55 on Thursday. <a href="https://www.benzinga.com/quote/BC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Roth MKM boosted Marvell Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>) price target from $60 to $95. Roth MKM analyst Suji Desilva maintained a Buy rating. Marvell Technology shares gained 4.6% to close at $85.09 on Thursday. <a href="https://www.benzinga.com/quote/MRVL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted the price target for Textron Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/txt#NYSE">TXT</a>) from $85 to $105. B of A Securities analyst Ronald Epstein upgraded the stock from Neutral to Buy. Textron shares fell 0.3% to close at $90.32 on Thursday. <a href="https://www.benzinga.com/quote/TXT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan increased Broadcom Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avgo#NASDAQ">AVGO</a>) price target from $1,550 to $1,700. JP Morgan analyst Harlan Sur maintained the stock with an Overweight rating. Broadcom shares gained 4.2% to close at $1,407.01 on Thursday. <a href="https://www.benzinga.com/quote/AVGO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan boosted the price target for General Electric Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ge#NYSE">GE</a>) from $166 to $180. JP Morgan analyst Seth Seifman upgraded the stock from Neutral to Overweight. General Electric shares gained 4.4% to close at $166.50 on Thursday. <a href="https://www.benzinga.com/quote/GE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased Micron Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mu#NASDAQ">MU</a>) price target from $95 to $125. Wells Fargo analyst Aaron Rakers maintained an Overweight rating. Micron shares gained 3.6% to close at $98.98 on Thursday. <a href="https://www.benzinga.com/quote/MU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson boosted MongoDB, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdb#NASDAQ">MDB</a>) price target from $405 to $430. DA Davidson analyst Rudy Kessinger upgraded the stock from Neutral to Buy. MongoDB shares gained 0.6% to close at $412.01 on Thursday. <a href="https://www.benzinga.com/quote/MDB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird increased Costco Wholesale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cost#NASDAQ">COST</a>) price target from $775 to $850. Baird analyst Peter Benedict maintained an Outperform rating. Costco shares gained 1.6% to close at $785.59 on Thursday. <a href="https://www.benzinga.com/quote/COST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised The Cigna Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ci#NYSE">CI</a>) price target from $370 to $385. Mizuho analyst Ann Hynes maintained a Buy rating. Cigna shares gained 0.9% to close at $342.74 on Thursday. <a href="https://www.benzinga.com/quote/CI/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/24/03/37557834/cisco-robinhood-and-2-other-stocks-insiders-are-selling"> Cisco, Robinhood And 2 Other Stocks Insiders Are Selling </a>